Cohen Chad M
Known title: Chief Financial OfficerCIK: 0001524314
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Adaptive Biotechnologies Fair Value Lifted on MRD Optimism. Adaptive Biotechnologies saw a modest increase in its fair value estimate driven by optimism regarding minimal residual disease (MRD) data. This development provides a fundamental reason for potential valuation adjustments, distinct from the technical indicators currently showing a negative divergence. The stock remains within its 52-week range, with analysts maintaining a higher average target price than the current market levels.
Transaction History
| GRND | ▲ Buy | Grant | 13,593 | $0 | 6/2/2026 | View on chart |
| GRND | ▲ Buy | Grant | 4,049 | $0 | 6/2/2026 | View on chart |
| GRND | ▲ Buy | Grant | 221 | $0 | 11/3/2025 | View on chart |
| GRND | ▲ Buy | Grant | 1,397 | $0 | 6/3/2025 | View on chart |
| GRND | ▲ Buy | Grant | 9,336 | $0 | 7/30/2024 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 10,000 | $73K | 12/22/2021 | View on chart |
| ADPT | ▼ Sell | Open Market | 10,000 | $300K | 12/22/2021 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 5,000 | $36K | 11/10/2021 | View on chart |
| ADPT | ▼ Sell | Open Market | 5,000 | $170K | 11/10/2021 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 5,000 | $36K | 11/9/2021 | View on chart |
| ADPT | ▼ Sell | Open Market | 5,000 | $180K | 11/9/2021 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 5,000 | $36K | 10/6/2021 | View on chart |
| ADPT | ▼ Sell | Open Market | 5,000 | $162K | 10/6/2021 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 5,000 | $36K | 10/5/2021 | View on chart |
| ADPT | ▼ Sell | Open Market | 5,000 | $163K | 10/5/2021 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 5,000 | $36K | 9/8/2021 | View on chart |
| ADPT | ▼ Sell | Open Market | 5,000 | $195K | 9/8/2021 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 9,375 | $61K | 9/7/2021 | View on chart |
| ADPT | ▼ Sell | Open Market | 9,375 | $372K | 9/7/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Grindr Expands HIV Prevention with New Deal and Acquisition
Grindr announced a new partnership with Freddie to support HIV prevention services. The company also bought PurposeMed for $250 million, adding telehealth for PrEP. These moves broaden Grindr’s role in HIV care and could increase its user base. The deal signals a shift toward health services beyond dating.
Grindr Expands HIV Prevention with New Deal and Acquisition. Grindr announced a new partnership with Freddie to support HIV prevention services. The company also bought PurposeMed for $250 million, adding telehealth for PrEP. These moves broaden Grindr’s role in HIV care and could increase its user base. The deal signals a shift toward health services beyond dating.